“…For instance, many studies show that SSRI administration reduces depression-like behavior, 5, 6 enhances neurogenesis, 7 increases brain-derived neurotrophic factor (BDNF) levels, 5, 8 reduces hypothalamic–pituitary–adrenal (HPA) axis activity 9, 10 and heightens long-term potentiation (LTP). 11 However, many others reported no or opposite effects concerning the same endpoints: behavior, 12, 13, 14, 15 neurogenesis, 16, 17, 18, 19, 20 BDNF levels, 21, 22, 23, 24, 25, 26 HPA axis activity 27, 28 and LTP. 29, 30 …”